OS and PFS on first-line imatinib or dasatinib therapy. Updated outcomes of Southwest Oncology Group Study S0325 (NCT00070499): “Imatinib Mesylate or Dasatinib in Treating Patients with Chronic Phase Chronic Myelogenous Leukemia” (courtesy of SWOG Statistical Center). The 3-year OS is 97% and 97% for dasatinib and imatinib, respectively; 3-year PFS is 93% and 91% for dasatinib and imatinib, respectively.